On November 18, 2021 Exact Sciences Corp. (NASDAQ: EXAS) reported an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test (Press release, Exact Sciences, NOV 18, 2021, View Source [SID1234595778]). This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims to evaluate MCED test safety and efficacy and help determine how to facilitate the implementation of effective MCED testing in the future.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We share in Jefferson’s deep commitment to building a patient and provider experience that addresses the needs of all populations, including the underserved and vulnerable, so that earlier cancer detection can have the greatest impact," said Kevin Conroy, chairman and CEO of Exact Sciences. "We’re thrilled to work with a leading health system like Jefferson to determine how MCED testing can be most effectively implemented and to develop the services required to support patients and primary care physicians."
Jefferson Health has a primary care network of more than 100 primary practices across Southeastern Pennsylvania and Southern New Jersey, serving over 125,000 adults who are eligible for cancer screening. A health system-based learning community has been organized to determine the impact of MCED testing on population health. The learning community includes health system leaders, primary care physicians, patients, clinical specialists, care coordinators, population health scientists, administrators, information technology personnel, and community representatives in collaboration with Jefferson’s NCI-designated Sidney Kimmel Cancer Center.
"We welcome the Exact Sciences team to our learning community and look forward to participating in research that allows us to ‘test and learn’ about MCED testing, including how to implement effective advances in cancer screening," said Bruce A. Meyer, MD, MBA, President of Jefferson Health. "We have a shared belief that earlier detection is the best way to bend the cancer mortality curve. We can make this vision a reality by working together to develop clinical pathways which will ultimately be used to deliver new early cancer detection technology and provide related services to the people we serve."
Jefferson is conducting developmental research on patient and provider engagement and plans to participate in Exact Sciences’ FDA registration study for its MCED test. Exact Sciences and Jefferson also plan to publish results of their work in this important area.